Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Integrated Phase II/III, Open Label, Randomized and Controlled Study of the Safety and Efficacy of CG0070 Adenovirus Vector Expressing GM-CSF in Patients With NMIBC With Carcinoma In Situ Disease Who Have Failed BCG

NCT01438112 is registered in ClinicalTrials.gov with CG Oncology, Inc. as lead sponsor.

NCT NCT01438112
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01438112 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Integrated Phase II/III, Open Label, Randomized and Controlled Study of the Safety and Efficacy of CG0070 Adenovirus Vector Expressing GM-CSF in Patients With NMIBC With Carcinoma In Situ Disease Who Have Failed BCG
Lead sponsor
CG Oncology, Inc.
Phase
Phase 2/3
Overall status
Terminated
Start date
March 31, 2014
Completion date
June 30, 2016
Enrollment
22 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, carcinoma in situ, carcinoma in situ concurrent with papillary tumors, transitional cell carcinoma